Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Total Non-Current Liabilities: 2017-2019

Historic Total Non-Current Liabilities for Cidara Therapeutics (CDTX) over the last 2 years, with Mar 2019 value amounting to $19.8 million.

  • Cidara Therapeutics' Total Non-Current Liabilities was N/A to $19.8 million in Q1 2019 from the same period last year, while for Mar 2019 it was $19.8 million, marking a year-over-year change of. This contributed to the annual value of $19.6 million for FY2018, which is N/A change from last year.
  • As of Q1 2019, Cidara Therapeutics' Total Non-Current Liabilities stood at $19.8 million, which was up 0.97% from $19.6 million recorded in Q4 2018.
  • Cidara Therapeutics' 5-year Total Non-Current Liabilities high stood at $24.8 million for Q2 2018, and its period low was $16.7 million during Q1 2017.
  • For the 3-year period, Cidara Therapeutics' Total Non-Current Liabilities averaged around $20.0 million, with its median value being $19.8 million (2019).
  • Data for Cidara Therapeutics' Total Non-Current Liabilities shows a peak YoY soared of 35.79% (in 2018) over the last 5 years.
  • Quarterly analysis of 3 years shows Cidara Therapeutics' Total Non-Current Liabilities stood at $16.8 million in 2017, then spiked by 35.79% to $19.6 million in 2018, then reached $19.8 million in 2019.
  • Its Total Non-Current Liabilities was $19.8 million in Q1 2019, compared to $19.6 million in Q4 2018 and $22.8 million in Q3 2018.